The Medtronic and Johnson & Johnson-backed epilepsy treatment system provider floated at the top of its range and saw its shares rise 47% on their first day.

NeuroPace, a US-based epilepsy treatment device developer backed by medical device maker Medtronic and pharmaceutical firm Johnson & Johnson, raised $102m yesterday in an initial public offering on the Nasdaq Global Select Market. The company priced 6 million shares at $17 each, at the upper end of the $15 to $17 range for the offering.…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.